Literature DB >> 23982851

Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).

R Andrés1, I Pajares, J Balmaña, G Llort, T Ramón Y Cajal, I Chirivella, E Aguirre, L Robles, E Lastra, P Pérez-Segura, N Bosch, C Yagüe, E Lerma, J Godino, M D Miramar, M Moros, P Astier, B Saez, M J Vidal, A Arcusa, S Ramón y Cajal, M T Calvo, A Tres.   

Abstract

BACKGROUND: BRCA1-associated breast cancers have been associated to a triple-negative phenotype. The prevalence of BRCA1 germline mutations in young onset TNBC based on informativeness of family history has not been reported. PATIENTS AND METHODS: From January 2008 to May 2009 were collected blood and tumor samples from patients with TNBC younger than 50 years and without a family history of breast and ovarian cancer in first- and second-degree relatives. Analysis of BRCA1 germline mutations was made. Age at diagnosis and informativeness of family history (presence of female in first- and second-degree relatives alive until age 45) was collected in all cases. Immunohistochemistry of basal-like features was performed centrally in all available tumors.
RESULTS: Seven pathogenic mutations were detected in 92 patients (7.6 %), two of them in patients younger than 35 years (28.6 %) (Fisher's exact test, p = 0.631). Three non-classified variants were detected (3.2 %). Family history was informative in two patients with a pathogenic mutation (28.6 %) and not informative in five (71.4 %) (Fisher's exact test, p = 0.121). Of the seven patients with a pathogenic mutation, four had a basal-like phenotype.
CONCLUSION: Patients with apparently sporadic TNBC younger than 50 years and a non-informative family history are candidates for germline genetic testing of BRCA1.

Entities:  

Mesh:

Year:  2013        PMID: 23982851     DOI: 10.1007/s12094-013-1070-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  22 in total

1.  Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.

Authors:  S A Vaziri; L M Krumroy; P Elson; G T Budd; G Darlington; J Myles; R R Tubbs; G Casey
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

2.  Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.

Authors:  Gelareh Farshid; Rosemary L Balleine; Margaret Cummings; Paul Waring
Journal:  Am J Surg Pathol       Date:  2006-11       Impact factor: 6.394

3.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.

Authors:  José Palacios; Emiliano Honrado; Ana Osorio; Alicia Cazorla; David Sarrió; Alicia Barroso; Sandra Rodríguez; Juan C Cigudosa; Orland Diez; Carmen Alonso; Enrique Lerma; Joaquín Dopazo; Carmen Rivas; Javier Benítez
Journal:  Breast Cancer Res Treat       Date:  2005-03       Impact factor: 4.872

4.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

5.  Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.

Authors:  R Lidereau; F Eisinger; M H Champème; C Noguès; I Bièche; D Birnbaum; C Pallud; J Jacquemier; H Sobol
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

6.  Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.

Authors:  Paul A James; Rebecca Doherty; Marion Harris; Bickol N Mukesh; Alvin Milner; Mary-Anne Young; Clare Scott
Journal:  J Clin Oncol       Date:  2006-02-01       Impact factor: 44.544

7.  Incorporating tumour pathology information into breast cancer risk prediction algorithms.

Authors:  Nasim Mavaddat; Timothy R Rebbeck; Sunil R Lakhani; Douglas F Easton; Antonis C Antoniou
Journal:  Breast Cancer Res       Date:  2010-05-18       Impact factor: 6.466

8.  Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Authors:  William D Foulkes; Kelly Metcalfe; Ping Sun; Wedad M Hanna; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Olufunmilayo I Olopade; Barbara L Weber; Jane McLennan; Ivo A Olivotto; Louis R Bégin; Steven A Narod
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

9.  Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.

Authors:  Hannaleena Eerola; Päivi Heikkilä; Anitta Tamminen; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna
Journal:  Breast Cancer Res       Date:  2005-04-21       Impact factor: 6.466

10.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Authors:  S R Young; Robert T Pilarski; Talia Donenberg; Charles Shapiro; Lyn S Hammond; Judith Miller; Karen A Brooks; Stephanie Cohen; Beverly Tenenholz; Damini Desai; Inuk Zandvakili; Robert Royer; Song Li; Steven A Narod
Journal:  BMC Cancer       Date:  2009-03-19       Impact factor: 4.430

View more
  14 in total

Review 1.  Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Konstantinos Nikolettos; Dimitrios Dimitroulis; Evangelos Diamantis; Paraskevi Farmaki; Alexandros Patsouras; Errika Voutyritsa; Athanasios Syllaios; Constantinos G Zografos; Efstathios A Antoniou; Nikos Nikolettos; Alkiviadis Kostakis; Konstantinos Kontzoglou; Dimitrios Schizas; Afroditi Nonni
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

Authors:  Fergus J Couch; Steven N Hart; Priyanka Sharma; Amanda Ewart Toland; Xianshu Wang; Penelope Miron; Janet E Olson; Andrew K Godwin; V Shane Pankratz; Curtis Olswold; Seth Slettedahl; Emily Hallberg; Lucia Guidugli; Jaime I Davila; Matthias W Beckmann; Wolfgang Janni; Brigitte Rack; Arif B Ekici; Dennis J Slamon; Irene Konstantopoulou; Florentia Fostira; Athanassios Vratimos; George Fountzilas; Liisa M Pelttari; William J Tapper; Lorraine Durcan; Simon S Cross; Robert Pilarski; Charles L Shapiro; Jennifer Klemp; Song Yao; Judy Garber; Angela Cox; Hiltrud Brauch; Christine Ambrosone; Heli Nevanlinna; Drakoulis Yannoukakos; Susan L Slager; Celine M Vachon; Diana M Eccles; Peter A Fasching
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

3.  miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.

Authors:  Insaf Fkih M'hamed; Maud Privat; Mounir Trimeche; Frédérique Penault-Llorca; Yves-Jean Bignon; Abderraouf Kenani
Journal:  Pathol Oncol Res       Date:  2017-01-18       Impact factor: 3.201

4.  Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

Authors:  Priyanka Sharma; Sara López-Tarruella; Jose Angel García-Saenz; Claire Ward; Carol S Connor; Henry L Gómez; Aleix Prat; Fernando Moreno; Yolanda Jerez-Gilarranz; Augusti Barnadas; Antoni C Picornell; Maria Del Monte-Millán; Milagros Gonzalez-Rivera; Tatiana Massarrah; Beatriz Pelaez-Lorenzo; María Isabel Palomero; Ricardo González Del Val; Javier Cortes; Hugo Fuentes Rivera; Denisse Bretel Morales; Iván Márquez-Rodas; Charles M Perou; Jamie L Wagner; Joshua M V Mammen; Marilee K McGinness; Jennifer R Klemp; Amanda L Amin; Carol J Fabian; Jaimie Heldstab; Andrew K Godwin; Roy A Jensen; Bruce F Kimler; Qamar J Khan; Miguel Martin
Journal:  Clin Cancer Res       Date:  2016-06-14       Impact factor: 12.531

Review 5.  Basal-like and triple-negative breast cancers: searching for positives among many negatives.

Authors:  Prasanna Alluri; Lisa A Newman
Journal:  Surg Oncol Clin N Am       Date:  2014-07       Impact factor: 3.495

6.  MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome.

Authors:  Imen Medimegh; Ines Omrane; Maud Privat; Nancy Uhrhummer; Hajer Ayari; Fadoua Belaiba; Farhat Benayed; Khaled Benromdhan; Sylvie Mader; Ives-Jean Bignon; Amel Benammar Elgaaied
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

7.  Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.

Authors:  Amanda B Spurdle; Fergus J Couch; Michael T Parsons; Lesley McGuffog; Daniel Barrowdale; Manjeet K Bolla; Qin Wang; Sue Healey; Rita Schmutzler; Barbara Wappenschmidt; Kerstin Rhiem; Eric Hahnen; Christoph Engel; Alfons Meindl; Nina Ditsch; Norbert Arnold; Hansjoerg Plendl; Dieter Niederacher; Christian Sutter; Shan Wang-Gohrke; Doris Steinemann; Sabine Preisler-Adams; Karin Kast; Raymonda Varon-Mateeva; Steve Ellis; Debra Frost; Radka Platte; Jo Perkins; D Gareth Evans; Louise Izatt; Ros Eeles; Julian Adlard; Rosemarie Davidson; Trevor Cole; Giulietta Scuvera; Siranoush Manoukian; Bernardo Bonanni; Frederique Mariette; Stefano Fortuzzi; Alessandra Viel; Barbara Pasini; Laura Papi; Liliana Varesco; Rosemary Balleine; Katherine L Nathanson; Susan M Domchek; Kenneth Offitt; Anna Jakubowska; Noralane Lindor; Mads Thomassen; Uffe Birk Jensen; Johanna Rantala; Åke Borg; Irene L Andrulis; Alexander Miron; Thomas V O Hansen; Trinidad Caldes; Susan L Neuhausen; Amanda E Toland; Heli Nevanlinna; Marco Montagna; Judy Garber; Andrew K Godwin; Ana Osorio; Rachel E Factor; Mary B Terry; Timothy R Rebbeck; Beth Y Karlan; Melissa Southey; Muhammad Usman Rashid; Nadine Tung; Paul D P Pharoah; Fiona M Blows; Alison M Dunning; Elena Provenzano; Per Hall; Kamila Czene; Marjanka K Schmidt; Annegien Broeks; Sten Cornelissen; Senno Verhoef; Peter A Fasching; Matthias W Beckmann; Arif B Ekici; Dennis J Slamon; Stig E Bojesen; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Jenny Chang-Claude; Dieter Flesch-Janys; Anja Rudolph; Petra Seibold; Kristiina Aittomäki; Taru A Muranen; Päivi Heikkilä; Carl Blomqvist; Jonine Figueroa; Stephen J Chanock; Louise Brinton; Jolanta Lissowska; Janet E Olson; Vernon S Pankratz; Esther M John; Alice S Whittemore; Dee W West; Ute Hamann; Diana Torres; Hans Ulrich Ulmer; Thomas Rüdiger; Peter Devilee; Robert A E M Tollenaar; Caroline Seynaeve; Christi J Van Asperen; Diana M Eccles; William J Tapper; Lorraine Durcan; Louise Jones; Julian Peto; Isabel dos-Santos-Silva; Olivia Fletcher; Nichola Johnson; Miriam Dwek; Ruth Swann; Anita L Bane; Gord Glendon; Anna M Mulligan; Graham G Giles; Roger L Milne; Laura Baglietto; Catriona McLean; Jane Carpenter; Christine Clarke; Rodney Scott; Hiltrud Brauch; Thomas Brüning; Yon-Dschun Ko; Angela Cox; Simon S Cross; Malcolm W R Reed; Jan Lubinski; Katarzyna Jaworska-Bieniek; Katarzyna Durda; Jacek Gronwald; Thilo Dörk; Natalia Bogdanova; Tjoung-Won Park-Simon; Peter Hillemanns; Christopher A Haiman; Brian E Henderson; Fredrick Schumacher; Loic Le Marchand; Barbara Burwinkel; Frederik Marme; Harald Surovy; Rongxi Yang; Hoda Anton-Culver; Argyrios Ziogas; Maartje J Hooning; J Margriet Collée; John W M Martens; Madeleine M A Tilanus-Linthorst; Hermann Brenner; Aida Karina Dieffenbach; Volke Arndt; Christa Stegmaier; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Annika Lindblom; Sara Margolin; Vijai Joseph; Mark Robson; Rohini Rau-Murthy; Anna González-Neira; José Ignacio Arias; Pilar Zamora; Javier Benítez; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Paolo Peterlongo; Daniela Zaffaroni; Monica Barile; Fabio Capra; Paolo Radice; Soo H Teo; Douglas F Easton; Antonis C Antoniou; Georgia Chenevix-Trench; David E Goldgar
Journal:  Breast Cancer Res       Date:  2014-12-23       Impact factor: 6.466

8.  MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer.

Authors:  Xingzeng Zhang; Genshun Ma; Jianchao Liu; Yajun Zhang
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

9.  Study of the Genetic Variants in BRCA1/2 and Non-BRCA Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina.

Authors:  Angela R Solano; Pablo G Mele; Fernanda S Jalil; Natalia C Liria; Ernesto J Podesta; Leandro G Gutiérrez
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

10.  Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.

Authors:  Iván Márquez-Rodas; Marina Pollán; María José Escudero; Amparo Ruiz; Miguel Martín; Ana Santaballa; Purificación Martínez Del Prado; Norberto Batista; Raquel Andrés; Antonio Antón; Antonio Llombart; Antonio Fernandez Aramburu; Encarnación Adrover; Sonia González; Miguel Angel Seguí; Lourdes Calvo; José Lizón; Álvaro Rodríguez Lescure; Teresa Ramón Y Cajal; Gemma Llort; Carlos Jara; Eva Carrasco; Sara López-Tarruella
Journal:  PLoS One       Date:  2017-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.